STAAR Surgical (STAA) Stock Forecast & Price Target

Staar Surgical is viewed positively because 2Q’26 showed a sharp operational inflection, with net sales of $93.5M up 111.0% year over year, gross margin expanding to 74.5%, and adjusted EBITDA surging to $20.0M, or a 21.4% margin, far above expectations. The core thesis rests on China recovery durability, as China revenue of $52.3M grew over 100% year over year and 10% sequentially on continued EVO+ adoption, with no evidence of inventory build and management expecting demand to be fully satisfied by the end of 3Q’26. In addition, the permanent CEO appointment removes a leadership overhang, while strong cash and investments of $181.5M, debt-free status, and a reiterated $225M FY’26 opex target support the company’s ability to keep compounding profitability and long-term value.

Staar Surgical is facing a weak fundamental backdrop because its core ICL franchise is showing slower-than-historical growth in China, where annual volume growth has recovered only to 3%-5% from 2023-2025 versus 10%-20% in 2016-2019, with affordability pressure and a soft macro environment shifting price-sensitive patients toward LASIK and SMILE. In the U.S., adoption remains structurally constrained because roughly 95% of refractive decisions start with optometrists, patients already request LASIK by name, and ICL lacks comparable category marketing, leaving surgeons to upsell a more expensive and less familiar procedure. Even where ICL’s clinical profile is viewed as superior, the roughly 50% higher cost, concentration in higher myopes, and the absence of a hyperopic U.S. indication support a longer, more difficult path to broader penetration and growth.